<DOC>
	<DOCNO>NCT02451540</DOCNO>
	<brief_summary>In study efficacy Roflumilast addition LAMA/LABA therapy assess use Functional Respiratory Imaging . In total 40 Chronic obstructive pulmonary disease ( COPD ) patient , Global Initiative Chronic Obstructive Lung Disease ( GOLD ) stag C D , stable LABA/LAMA therapy prone dynamic hyperinflation include study . To indicate susceptibility dynamic hyperinflation patient baseline Borg Fatigue score 6-minute walk test ( 6MWT ) 4 . The patient randomize way 1 2 patient receive placebo 1 active component . Image parameter assess correlation lung function health relate quality life check treatment .</brief_summary>
	<brief_title>Evaluation Effect Roflumilast Hyperinflated COPD Patients Using Functional Respiratory Imaging</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Male female patient ≥ 30 year old Written inform consent obtain Patient Body mass index ( BMI ) ≥ 20 Female patient childbearing potential confirm contraception method use least 14 day visit 1 continue use contraception method study COPD patient GOLD stag C D Patient Borg Fatigue score 6MWT screen 4 indicate susceptibility dynamic hyperinflation Patient smoke history least 10 packyears Patient take combination therapy LABA/ LAMA least 6 week visit 1 Patient must able understand complete protocol requirement , instruction , questionnaire protocolstated restriction Pregnant lactate female Patient severe immunological disease and/ severe acute infectious disease Patient heart failure document medical history define investigator physical examination perform visit 1 Patient diagnosis cancer ( except basal cell carcinoma ) Patient history depression associate suicidal ideation behaviour Patient moderate severe hepatic impairment . Patient lactose intolerance Patient unlikely comply protocol unable understand nature , scope possible consequence study . Patient receive inhalation corticosteroid ( ICS ) within last 6 week prior screen visit Patient receive investigational new drug within last 4 week prior screen visit twice duration biological effect drug ( whichever longer )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pulmonary Disease , Chronic Obstructive</keyword>
	<keyword>dynamic hyperinflation</keyword>
	<keyword>Computed Tomography scan</keyword>
	<keyword>CT scan</keyword>
	<keyword>Functional Respiratory Imaging</keyword>
	<keyword>FRI</keyword>
	<keyword>Roflumilast</keyword>
	<keyword>PRO</keyword>
</DOC>